1 / 6

Global CAR T-Cell therapy Market is Expected to Reach $6.1 Billion by 2031

The car t-cell therapy market was valued at $1.7 billion in 2021, and is estimated to reach $6.1 billion by 2031, growing at a CAGR of 13.5% from 2022 to 2031.

Allied6
Télécharger la présentation

Global CAR T-Cell therapy Market is Expected to Reach $6.1 Billion by 2031

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CAR T-Cell therapy Market

  2. Global CAR T-Cell therapy Market is Expected to Reach $6.1 Billion by 2031: Allied Market Research According to a new report published by Allied Market Research, titled, “CAR T-Cell therapy Market," The car t-cell therapy market was valued at $1.7 billion in 2021, & is estimated to reach $6.1 billion by 2031, growing at a CAGR of 13.5% from 2022 to 2031. Chimeric antigen receptor (CAR) T-cell therapy treats certain cancer by turning T-cells into more efficient cancer-fighting cells. CAR T-cell therapy is a novel targeted approach, which involves genetic engineering of T- cells to specifically target the receptors on cancer cells. Key Findings Of The Study – • By drug type, the axicabtagene ciloleucel segment held the largest share in the CAR T-cell therapy market in 2021. • By indication, the lymphoma segment held the largest share in the CAR T-cell therapy market in 2021. • By end user, the cancer centers segment is expected to show the fastest market growth during the forecast period.

  3. Covid-19 Scenario: The COVID-19 outbreak is anticipated to have a negative impact on the market, as huge number of medical college and hospitals across the globe were restructured to increase the hospital capacity for patients diagnosed with COVID-19. • The significant reduction in clinical trials due to strict government guidelines against COVID-19, resists the growth of CAR T-cell therapy market size. • Download Free Sample Report at: https://www.alliedmarketresearch.com/request- sample/17358

  4. List of Key Players Profiled in The Report: Autolus Therapeutics, Bluebird bio, Inc., Bristol-Myers Squibb, Caribou Biosciences, Inc., Cartesian Therapeutics, Inc., Celgene Corporation, Cellectis, Celyad Oncology, Gilead Sciences, Inc. (Kite Pharma Inc.), Intellia Therapeutics, Juno Therapeutics, Inc., Merck & Co., Inc., Miltenyi Biotech, Novartis AG, Pfizer, Inc., Sorrento Therapeutics, Inc. • • • • • • • • • • • • • • •

  5. ABOUT US Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry. Contact: David Correa 5933 NE Win Sivers Drive#205, Portland, OR 97220 United States, USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141, UK: +44-845-528-1300, Hong Kong: +852-301-84916, India (Pune) help@alliedmarketresearch.com Follow Us on LinkedIn: https://www.linkedin.com/company/allied-market-research

  6. THANK YOU

More Related